Biocatalysis is a Key Technology for Successful Chiral Synthesis

Oct 16, 2013

It is now well-recognised that the need for green, economic, robust and scaleable processes is at the forefront of customer research plans for the synthesis of chiral APIs and intermediates. Tom Moody and Stefan Mix at Almac, provides an overview of how the chemical industry is under severe pressure to make their chemical processes greener, lower costs, minimise waste and shorten existing syntheses. ...

Read More

Partnering to Drive Innovation – A Supercritical Success Story

Oct 16, 2013

Paul Titley at Aesica Pharmaceuticals and Peter York at Crystec Pharma, discuss the design, development and manufacture of modern medicines pose numerous scientific and technical challenges to drug delivery and pharmaceutical companies. Increasingly, companies are finding that approaches which have traditionally been used to overcome these problems and in-house experience/expertise available are no longer appropriate or sufficiently versatile to solve many of the emerging issues. ...

Read More

Supplementary Protection for Medicines – Functioning or Failing?

Oct 16, 2013

The legislation governing Supplementary Protection Certificates for medicinal products, EU Regulation No. 469/2009 ‘the Regulation’, scores well on brevity but it falls down badly when it comes to clarity. David Rose at SJ Berwin LLP, considers whether the “dysfunctional” label is merited and if so why. In doing so, three specific aspects of the SPC system will be considered: combination therapies, new indications and active ingredients. ...

Read More

Compounding Success: Patenting Known Molecules in Europe and the UK

Oct 16, 2013

Once an inventor has identified a candidate pharmaceutical molecule, the prime objective should be to secure patent protection for the molecule itself together with the largest group of similar compounds that the patent examiner will allow. However, how should the inventor proceed if the molecule is already published in the prior art or indeed already covered by an existing patent? Dr Matt Barton at Forresters, looks at some other types of patent claims that the inventor can use to obtain patent protection for the candidate molecule. ...

Read More

Life Science Austria: Advancing Life Science at the Heart of Europe

Oct 16, 2013

Over the past decade, Austria has established itself as a well-respected hub of the life science industry. Region by region, the life science industry has spread across Austria, from the capital, Vienna, to the powerhouses of Styria, Tyrol and Upper and Lower Austria. Sonja Polan at Life Science Austria looks into a region and how it has its own special culture and particular strengths that are reflected in the local companies who are organised through regional life science clusters. ...

Read More